# US 2025/0082571 A1 · Compositions and methods for delivery of il-2 and anti-il-2 for treatment of rheumatoid arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082571 A1
- Document ID: US20250082571A1
- Status: Published application
- Kind: A1
- Application number: 18/721,326
- Filed: 2022-12-21
- Published: 2025-03-13
- Earliest claimed: 2021-12-23
- Assignees: Arizona Board of Regents on behalf of Arizona State University; Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Arizona Board of Regents on behalf of Arizona State University; Arizona Board of Regents on Behalf of the University of Arizona
- Inventors: Abhinav Acharya; Hsin-Jung (Joyce) Wu
- Web page: https://patentgrep.com/patent/US20250082571A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61L 27/52: Hydrogels or hydrocolloids
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 38/2013: {IL-2}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/246: {IL-2}
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/256: Antibodies, e.g. immunoglobulins, vaccines
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a sustained drug release system comprising IL-2 and anti-IL-2 incorporated into a thermosensitive hydrogel that is engineered to be in liquid form at low temperatures for delivery, but form a hydrogel at physiological body temperatures to act as a sustained release platform. The thermostable hydrogel solution slowly releases IL-2 and anti-IL-2 to provide optimal concentrations for effective treatment of autoimmune diseases.

## Claims

### Claim 1

A thermosensitive hydrogel composition comprising:
a) at least one biologically compatible polymer; and
b) at least one biologically active agent selected from the group consisting of: an IL-2 polypeptide component, an anti-IL-2 antibody component and a combination thereof; and wherein the composition is liquid at or below room temperature but forms a gel at about 37° C.

### Claim 2 (depends on 1)

The thermosensitive hydrogel of claim 1, comprising at least one biologically compatible polymer selected from the group consisting of: poly(D,L-lactide-co-glycolide) (PLGA)-poly(ethylene glycol) (PEG)-(PLGA); poly(lactic acid) (PLA)-(PEG)-(PLA); and poly(lactide-co-caprolactone) (PLCL)-(PEG)-(PLCL).

### Claim 3 (depends on 1)

The thermosensitive hydrogel of claim 1, comprising at least one polyurethane based polymer.

### Claim 4 (depends on 1)

The thermosensitive hydrogel composition of claim 1, wherein the IL-2 polypeptide component is selected from the group consisting of IL-2 polypeptide, a recombinant IL-2 polypeptide, and an active IL-2 polypeptide fragment.

### Claim 5 (depends on 1)

The thermosensitive hydrogel composition of claim 1, wherein the composition comprises a combination of an IL-2 polypeptide and an anti-IL-2 antibody.

### Claim 6 (depends on 1)

The thermosensitive hydrogel composition of claim 1, comprising an IL-2 antigen:anti-IL-2 complex or a molecule resembling an IL-2 antigen:anti-IL-2 complex.

### Claim 7 (depends on 1)

The thermosensitive hydrogel composition of claim 1, wherein the composition is a low viscosity liquid at room temperature.

### Claim 8 (depends on 1)

A method of treating a disease or disorder, the method comprising administering an effective amount of at least one thermosensitive hydrogel of claim 1 to a subject in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the thermosensitive hydrogel comprises at least one biologically compatible polymer selected from the group consisting of: poly(D,L-lactide-co-glycolide) (PLGA)-poly(ethylene glycol) (PEG)-(PLGA); poly(lactic acid) (PLA)-(PEG)-(PLA); and poly(lactide-co-caprolactone) (PLCL)-(PEG)-(PLCL).

### Claim 10 (depends on 8)

The method of claim 8, comprising at least one polyurethane based polymer.

### Claim 11 (depends on 8)

The method of claim 8, wherein the IL-2 polypeptide component is selected from the group consisting of IL-2 polypeptide, a recombinant IL-2 polypeptide, and an active IL-2 polypeptide fragment.

### Claim 12 (depends on 8)

The method of claim 8, comprising an IL-2 antigen:anti-IL-2 complex or a molecule resembling an IL-2 antigen:anti-IL-2 complex.

### Claim 13 (depends on 8)

The method of claim 8, wherein the composition is administered as a low viscosity liquid.

### Claim 14 (depends on 8)

The method of claim 8, wherein the composition is administered by way of injection.

### Claim 15 (depends on 8)

The method of claim 8, wherein the disease or disorder is an autoimmune disease or disorder.

### Claim 16 (depends on 8)

The method of claim 8, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis (RA), type-1 diabetes (T1D), idiopathic inflammatory myopathies, multiple sclerosis, traumatic brain injury, wound healing, inflammatory diseases, pemphigus, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, polymyositis, dermatomyositis, Sjogren's syndrome and different forms of vasculitis.

### Claim 17 (depends on 1)

A kit comprising at least one thermostable hydrogel of claim 1.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the kit is formulated for storage at or below room temperature to maintain the thermostable hydrogel composition as a liquid.
